Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Hematologic toxicities of small molecule tyrosine kinase inhibitors.

Barber NA, Afzal W, Akhtari M.

Target Oncol. 2011 Dec;6(4):203-15. doi: 10.1007/s11523-011-0202-9. Epub 2011 Nov 30. Review.

PMID:
22127751
2.

Hematologic toxicities associated with intravenous immunoglobulin therapy.

Baxley A, Akhtari M.

Int Immunopharmacol. 2011 Nov;11(11):1663-7. doi: 10.1016/j.intimp.2011.07.024. Epub 2011 Aug 16. Review.

PMID:
21843660
3.

Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials.

Schutz FA, Je Y, Choueiri TK.

Crit Rev Oncol Hematol. 2011 Nov;80(2):291-300. doi: 10.1016/j.critrevonc.2010.11.007. Epub 2011 Feb 20.

PMID:
21339073
4.

Drug-associated disease: hematologic dysfunction.

Vandendries ER, Drews RE.

Crit Care Clin. 2006 Apr;22(2):347-55, viii. Review.

PMID:
16678004
5.

Hematologic toxicity of sodium valproate.

Acharya S, Bussel JB.

J Pediatr Hematol Oncol. 2000 Jan-Feb;22(1):62-5. Review.

PMID:
10695824
6.

Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use.

Dasanu CA, Padmanabhan P, Clark BA 3rd, Do C.

Expert Opin Drug Saf. 2012 May;11(3):445-57. doi: 10.1517/14740338.2012.672971. Epub 2012 Apr 2. Review.

PMID:
22469002
7.

Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.

Hartmann JT, Haap M, Kopp HG, Lipp HP.

Curr Drug Metab. 2009 Jun;10(5):470-81. Review.

PMID:
19689244
8.

Moving towards dose individualization of tyrosine kinase inhibitors.

Kl├╝mpen HJ, Samer CF, Mathijssen RH, Schellens JH, Gurney H.

Cancer Treat Rev. 2011 Jun;37(4):251-60. doi: 10.1016/j.ctrv.2010.08.006. Epub 2010 Sep 15. Review.

PMID:
20833478
9.

[Hematological side effects of tyrosine kinase inhibition using imatinib].

Schmitt-Graeff A, Hochhaus A.

Pathologe. 2006 Feb;27(1):40-6. German.

PMID:
16421705
10.

Therapeutic protein kinase inhibitors.

Grant SK.

Cell Mol Life Sci. 2009 Apr;66(7):1163-77. doi: 10.1007/s00018-008-8539-7. Review.

PMID:
19011754
11.

How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors?

Chan A, Tan EH.

Support Care Cancer. 2011 Oct;19(10):1667-74. doi: 10.1007/s00520-010-0999-2. Epub 2010 Sep 5.

PMID:
20820812
12.

Hematologic adverse effects of clopidogrel.

Balamuthusamy S, Arora R.

Am J Ther. 2007 Jan-Feb;14(1):106-12. Review.

PMID:
17303978
13.

Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes.

Mokhtari D, Welsh N.

Clin Sci (Lond). 2009 Nov 9;118(4):241-7. doi: 10.1042/CS20090348. Review.

PMID:
19886867
14.

Hematologic side effects of drugs.

Lubran MM.

Ann Clin Lab Sci. 1989 Mar-Apr;19(2):114-21. Review.

PMID:
2665627
15.

Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.

Steeghs N, Nortier JW, Gelderblom H.

Ann Surg Oncol. 2007 Feb;14(2):942-53. Epub 2006 Nov 14. Review.

PMID:
17103252
16.

Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors.

Chintalgattu V, Patel SS, Khakoo AY.

Hematol Oncol Clin North Am. 2009 Feb;23(1):97-107, viii-ix. doi: 10.1016/j.hoc.2008.11.004. Review.

PMID:
19248973
17.

[Management of adverse effects of targeted therapy toxicities in oncology].

Coquan E, Henri P, de Raucourt S, Lireux B, Lamy E, Delcambre C, Sevin E, Dutriaux C, Bouhier-Leporrier K, Gervais R, Joly F.

Rev Prat. 2012 Jan;62(1):17-25. French.

PMID:
22335060
18.

Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.

Bunn PA Jr, Thatcher N.

Oncologist. 2008;13 Suppl 1:37-46. doi: 10.1634/theoncologist.13-S1-37. Review.

19.

What kind of rash is it?: deciphering the dermatologic toxicities of biologic and targeted therapies.

Esper P, Gale D, Muehlbauer P.

Clin J Oncol Nurs. 2007 Oct;11(5):659-66. Review.

PMID:
17962174
20.

Pulmonary toxicities from targeted therapies: a review.

Barber NA, Ganti AK.

Target Oncol. 2011 Dec;6(4):235-43. doi: 10.1007/s11523-011-0199-0. Epub 2011 Nov 11. Review.

PMID:
22076388

Supplemental Content

Support Center